ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Biomarkers"

  • Abstract Number: 162 • 2020 Pediatric Rheumatology Symposium

    Minor Biomarkers in Juvenile Idiopathic Arthritis (JIA)

    Terry Moore1, Austin Dalrymple 2, Lance Feller 3 and Paul Tuttle 4, 1ST. LouisUniv12651729, St. Louis, Missouri, 2Saint Louis University School of Medicine, Saint Louis, Missouri, 3Orlando, Florida, 4OSMS, Hobart, Wisconsin

    Background/Purpose: JIA is a heterogeneous group of patients with varying types of biomarkers detected in a small percentage of patients. More specific biomarkers would help…
  • Abstract Number: 163 • 2020 Pediatric Rheumatology Symposium

    Anti-Dense Fine Speckled (DFS) Autoantibodies in Autoinflammatory Vasculopathies

    Asa Laestadius1, May Choi 1, Marvin Fritzler 1, Aurore Fifi-Mah 2, Susanne Benseler 3 and Joao Dantas 1, 1University of Calgary, Calgary, Canada, 2Calgary, Canada, 3Univeristy of Calgary, Calagry, Canada

    Background/Purpose: Autoantibodies to dense fine speckles 70 (DFS70) is now recognized to be more common among apparently healthy individuals compared to patients with ANA-related rheumatic…
  • Abstract Number: 014 • 2020 Pediatric Rheumatology Symposium

    Successful Validation of a Rapid Point-of-care Test for Serum Calprotectin (MRP8/14) as Biomarker in Juvenile Idiopathic Arthritis

    Dirk Foell1, Carolin Park 2, Linda Ziegler 2, Dirk Holziner 3, Kirsten Minden 4, Renato Cotti 5 and Jakob Weber 5, 1University Hospital Muenster, Muenster, Nordrhein-Westfalen, Germany, 2University of Muenster, Muenster, Germany, 3University of Essen, Essen, Germany, 4Berlin, Germany, 5Buehlmann Laboratories, Schoenenbuch, Switzerland

    Background/Purpose: Treat-to-target strategies are established for the therapeutic approach to patients suffering from juvenile idiopathic arthritis (JIA). Another proposed therapeutic concept in pediatric rheumatology involves…
  • Abstract Number: 022 • 2020 Pediatric Rheumatology Symposium

    Association of Plasma Metabolomic Profiles with Methotrexate Response in Juvenile Idiopathic Arthritis

    Ryan Funk1 and Mara Becker 2, 1University of Kansas, Leawood, Kansas, 2Duke University Medical Center/Duke Clinical Research Institute, Chapel Hill

    Background/Purpose: Despite efforts to identify biomarkers to guide therapy in the treatment of juvenile idiopathic arthritis (JIA), drug therapy remains a trial-and-error process. In the…
  • Abstract Number: 055 • 2020 Pediatric Rheumatology Symposium

    Differential Analysis of Serum and Urine S100 Proteins in Juvenile-onset Systemic Lupus Erythematosus (jSLE)

    Sean Donohue 1, Angela Midgley 1, Jennifer Davies 1, Rachael Wright 1, Ian Bruce 2, Michael Beresford 1 and Christian Hedrich1, 1University of Liverpool, Liverpool, United Kingdom, 2The University of Manchester, Manchester, United Kingdom

    Background/Purpose: Juvenile-onset systemic lupus erythematosus (jSLE) is a systemic autoimmune/inflammatory disease. Up to 80% of patients develop lupus nephritis (LN) that affects treatment and prognosis(1-3).…
  • Abstract Number: 079 • 2020 Pediatric Rheumatology Symposium

    Traditional Laboratory Parameters and New Biomarkers in Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis

    Arianna De Matteis 1, Denise Pires Marafon 2, Ivan Caiello 2, Manuela Pardeo 2, Giulia Marucci 2, Emanuela Sacco 2, Giusi Prencipe 2, Fabrizio De Benedetti 2 and Claudia Bracaglia2, 1Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Lazio, Italy, 2Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy

    Background/Purpose: Macrophage Activation Syndrome (MAS) and Secondary Hemophagocytic Lymphohistiocytosis (sHLH) are hyperinflammatory conditions caused by a cytokine storm. Prompt recognition and early treatment are essential…
  • Abstract Number: L02 • 2019 ACR/ARP Annual Meeting

    Multiple Industrial Air Pollutants and Anti-Citrullinated Protein Antibody Positivity

    Naizhuo Zhao 1, Audrey Smargiassi 2, Marianne Hatzopoulou 3, Ines Colmegna 4, Marie Hudson 5, Marvin Fritzler 6, Philip Awadalla 7 and Sasha Bernatsky8, 1Research Institute of the McGill University Health Centre, Montreal, Canada, 2University of Montreal, Montreal, Canada, 3University of Toronto, Toronto, Canada, 4McGill University Health Center, Montreal, QC, Canada, 5Jewish General Hospital, Lady Davis Institute for Medical Research, and Department of Medicine, McGill University, Montreal, Canada, 6Cumming School of Medicine, University of Calgary, Calgary, Canada, 7Ontario Institute for Cancer Research, Toronto, Canada, 8Research Institute of the McGill University Health Centre, Montreal, QC, Canada

    Background/Purpose: Studies of associations between industrial air emissions and rheumatic disease, or diseases-related serological biomarkers, are few. Moreover, previous evaluations typically studied individual (not mixed)…
  • Abstract Number: L05 • 2019 ACR/ARP Annual Meeting

    Safety, Tolerability, Pharmacokinetics, and Clinical Outcomes Following Single-Dose IA Administration of UBX0101, a Senolytic MDM2/p53 Interaction Inhibitor, in Patients with Knee OA

    Benjamin Hsu1, Jennifer Visich 2, Mark Genovese 3, Kimberly Walter 2, Mahru An 4, Remi-Martin Laberge 4 and Jamie Dananberg 4, 1Unity Biotechnology, Brisbane, 2Unity Biotechnology, Brisbane, California, 3Stanford University, Stanford, CA, 4Unity Biotechnology, Brisbane, CA

    Background/Purpose: A non-drug biomarker study showed senescent cell (SnC) burden in OA synovial tissue to correlate with disease severity, inflammation, and knee pain (C. Yohn,…
  • Abstract Number: L15 • 2019 ACR/ARP Annual Meeting

    Efficacy, Safety, and Pharmacodynamic Effects of the Bruton’s Tyrosine Kinase Inhibitor, Fenebrutinib (GDC-0853), in Moderate to Severe Systemic Lupus Erythematosus: Results of a Phase 2 Randomized Controlled Trial

    David Isenberg1, Richard Furie 2, Nicholas Jones 3, Pascal Guibord 4, Joshua Galanter 5, Chin Lee 3, Anna McGregor 3, Balazs Toth 3, Julie Rae 3, Olivia Hwang 3, Pedro Miranda 6, Viviane de Souza 7, Juan Jaller-Raad 8, Anna Maura Fernandes 9, Rodrigo Garcia Salinas 10, Leslie Chinn 3, Michael Townsend 11, Alyssa Morimoto 3 and Katie Tuckwell 12, 1University College London, London, United Kingdom, 2Northwell Health, Great Neck, NY, 3Genentech, Inc., South San Francisco, California, 4Hoffmann-La Roche Limited, Mississauga, Canada, 5Genentech, Inc., SOUTH SAN FRANCISCO, 6Centro Estudios Reumatologicos, Santiago, Chile, 7Centro Mineiro de Pesquisas, Juiz de Fora, Minas Gerais, Brazil, 8Centro de Reumatologia y Ortopedia, Cimedical, Barranquilla, Colombia, 9Mario Covas Hospital, Santo Andre, Sao Paulo, Brazil, 10Hospital Italiano de La Plata, La plata, Buenos Aires, Argentina, 11Genentech, Inc., San Fransisco, 12Genentech, Inc., South San Francisco, CA

    Background/Purpose: Fenebrutinib (GDC-0853, FEN) is an oral, non-covalent, and highly selective inhibitor of Bruton’s tyrosine kinase (BTK) in clinical development for autoimmune diseases. The efficacy,…
  • Abstract Number: 1364 • 2019 ACR/ARP Annual Meeting

    Affect of Obesity on Multi-Biomarker Disease Activity (MBDA) Measurements in Rheumatoid Arthritis (RA) Patients

    Yael Ross1, Madhavi Siddhanthi 2, Lewis VanBrackle 3, David Carpenter 4, Aishwarya Rallabhandy 5 and Mohammad Kamran 2, 1WellStar Kennestone regional medical center, Atlanta, GA, 2WellStar Medical Group, Marietta, GA, 3Kennesaw State University, Kennesaw, 4WellStar Kennestone regional medical center, Marietta, 5High School, Marietta

    Background/Purpose: The goal for treatment of RA is to obtain low disease activity for better outcomes. In order to achieve low disease activity, it is…
  • Abstract Number: 2405 • 2019 ACR/ARP Annual Meeting

    Protein Biomarkers Predicting the Response to IFX+MTX+LEF Treatment in Patients with Rheumatoid Arthritis

    Jian Chen 1, Meng-shi Tang 2, Li-chang Xu 3, Shu Li 2, Yan Ge 2, Jing Tian 2, Xi Xie 2, Jin-wei Chen 2, Jin-feng Du 2 and Fen Li1, 1Department of Rheumatology and Immunology, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China, Changsha, 2Department of Rheumatology and Immunology, The Second Xiangya Hospital, Central South University, Changsha, 3International Department of YALI High School, Changsha

    Background/Purpose: Patients with rheumatoid arthritis (RA) usually receive triple therapy with methotrexate (MTX), leflunomide (LEF) and infliximab (IFX), but nearly one-third of them do not…
  • Abstract Number: 45 • 2019 ACR/ARP Annual Meeting

    bDMARD-experienced Filgotinib-treated Patient Samples Exhibit a Partial Reversion to the Peripheral Molecular Profile of a Demographically Matched Healthy Population

    Peter Taylor1, Emon Elboudwarej 2, Bryan Downie 3, Lene Vestergaard 2, Jinfeng Liu 2, Amer M. Mirza 2 and Rachael Hawtin 2, 1University of Oxford, Oxford, United Kingdom, 2Gilead Sciences, Inc., Foster City, CA, 3Gilead Sciences, Inc., Foster Citty, CA

    Background/Purpose: Filgotinib (FIL), an oral, selective, Janus Kinase 1 (JAK1) inhibitor was effective in Phase 3 studies of active RA in patients (pts) with inadequate…
  • Abstract Number: 1392 • 2019 ACR/ARP Annual Meeting

    The Relationship Between Abatacept Exposure and CD86 Receptor Occupancy in Rheumatoid Arthritis Patients Following Subcutaneous Administration and Its Association to Patient Outcomes

    Grigor Abelian1, Sheng Gao 2, Yash Gandhi 1, Blisse Vakkalagadda 1, Vidya Perera 1 and Bindu Murthy 1, 1Bristol-Myers Squibb, Princeton, 2Bristol-Myers Squibb, Princeton, NJ

    Background/Purpose: The purpose of this investigation was to characterize the relationship between systemic exposure of abatacept and measures of target engagement to further support dosing…
  • Abstract Number: 2417 • 2019 ACR/ARP Annual Meeting

    A Phase 2a Study of MEDI5872 (AMG557), a Fully Human Anti-ICOS Ligand Monoclonal Antibody in Patients with Primary Sjögren’s Syndrome

    Xavier Mariette1, Michele Bombardieri 2, Ilias Alevizos 3, Rachel Moate 4, Barbara Sullivan 5, Ghaith Noaiseh 6, Marika Kvarnström 7, William Rees 3, Liangwei Wang 3 and Gabor Illei 3, 1Université Paris-Sud, Paris, France, Paris, Centre, France, 2Queen Mary University of London, London, UK, London, United Kingdom, 3Viela Bio, Gaithersburg, MD, USA, Gaithersburg, MD, 4AstraZeneca, Cambridge, UK, Cambridge, United Kingdom, 5Amgen Inc., South San Francisco, CA, USA, South San Francisco, CA, 6University of Pittsburgh, PA, USA, Pittsburgh, PA, 7Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden

    Background/Purpose: The interaction of inducible T cell costimulatory ligand (ICOSL) and the ICOS receptor is key in the pathogenesis of primary Sjögren’s syndrome (pSS). MEDI5872…
  • Abstract Number: 530 • 2019 ACR/ARP Annual Meeting

    Phase I Evaluation of the PDE4 Inhibitor LY2775240: Head to Head Comparison with Apremilast Using an Ex Vivo Pharmacodynamic Assay

    Daniel Dairaghi1, Karen Cox 1, Stephen Ho 1, Paul Klekotka 2, Diane Phillips 1, Jean Lim 3, Shweta Urva 1 and Dipak Patel 2, 1Eli Lilly and Company, Indianapolis, IN, 2Eli Lilly and Company, San Diego, CA, 3Eli Lilly and Company, singapore, Singapore

    Background/Purpose: LY2775240 is a potent and selective phosphodiesterase (PDE4) inhibitor being investigated as a potential treatment for inflammatory disorders, such as psoriasis. PDE4 is expressed…
  • « Previous Page
  • 1
  • …
  • 63
  • 64
  • 65
  • 66
  • 67
  • …
  • 109
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology